11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004
1 Time to Triple Drug Class Failure after Initiation of HAART. A Mocroft, B Ledergerber, J P Viard, S Staszewski, M Murphy, A Chiesi, A Horban, A B Hansen, A N Phillps, J D Lundgren and the EuroSIDA Study Group.
2 Hepatitis B and Hepatitis C in the EuroSIDA Cohort: Prevalence and Effect on Mortality, AIDS Progression and Response to HAART. J Rockstroh, D Konopnicki, V Soriano, O Kirk, F Antunes, B Knysz, C Tural, S De Wit, A Mocroft, J Lundgren and the EuroSIDA Study Group.
XV International AIDS Conference, July 2004, Bangkok
1 Comparison of observed clinical event rates in the ESPRIT trial with projections from the EuroSIDA study. J D Lundgren, A Mocroft, J Bebchuck, S. Staszewski, F Antunes, B Knysz, M Law, A N Phillips, J Neaton.
(ESPRIT/EuroSIDA WePeB5685) abstract
6th International Conference on Adverse Drug Reactions and Lipodystrophy in HIV, October 2004, Washington
1 Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen. A Mocroft, AN Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, JD Lundgren for the EuroSIDA study group.
7th International Congress on Drug Therapy in HIV Infection, November 2004 Glasgow
1 Interruption/stopping HAART and risk of clinical disease progression to AIDS/death in EuroSIDA. C Holkmann-Olsen, A Mocroft, S Vella, A Blaxhult, N Clumeck, O Kirk, M Fisher, C Katlama, A Phillips, J Lundgren
2 Why do patients stop antiretrovirals used as part of an initial HAART regimen? Results from the EuroSIDA study group. A Mocroft, A Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, J Lundgren
4 HIV-patients across Europe: regional differences in patient characteristics. D Podlekareva, W Bannister, L Viksna, A Mocroft, B Knysz, P Reiss, N Chentsova, D Duiculescu, JD Lundgren, O Kirk, The EuroSIDA Study.